These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31041475)

  • 1. Efficacy and safety of elcatonin in postmenopausal women with osteoporosis: a systematic review with network meta-analysis of randomized clinical trials.
    Chen WC; Lin EY; Kang YN
    Osteoporos Int; 2019 Sep; 30(9):1723-1732. PubMed ID: 31041475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of parathyroid hormone (1-34) and elcatonin in postmenopausal women with osteoporosis: an 18-month randomized, multicenter controlled trial in China.
    Li Y; Xuan M; Wang B; Yang J; Zhang H; Zhang XZ; Guo XH; Lü XF; Xue QY; Yang GY; Ji QH; Liu ZM; Li CJ; Wu TF; Sheng ZY; Li PQ; Tong JC
    Chin Med J (Engl); 2013 Feb; 126(3):457-63. PubMed ID: 23422107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
    O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
    Cochrane Database Syst Rev; 2006 Jul; (3):CD005326. PubMed ID: 16856092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additive effect of elcatonin to risedronate for chronic back pain and quality of life in postmenopausal women with osteoporosis: a randomized controlled trial.
    Hongo M; Miyakoshi N; Kasukawa Y; Ishikawa Y; Shimada Y
    J Bone Miner Metab; 2015 Jul; 33(4):432-9. PubMed ID: 25123562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial.
    Binkley N; Bone H; Gilligan JP; Krause DS
    Osteoporos Int; 2014 Nov; 25(11):2649-56. PubMed ID: 25027109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
    Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
    Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis.
    Yang L; Kang N; Yang JC; Su QJ; Liu YZ; Guan L; Liu T; Meng XL; Wang Y; Hai Y
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2640-2668. PubMed ID: 30964193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of menatetrenone in the management of osteoporosis: a systematic review and meta-analysis of randomized controlled trials.
    Su S; He N; Men P; Song C; Zhai S
    Osteoporos Int; 2019 Jun; 30(6):1175-1186. PubMed ID: 30734066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of 5-year treatment with elcatonin and alfacalcidol on lumbar bone mineral density and the incidence of vertebral fractures in postmenopausal women with osteoporosis: a retrospective study.
    Iwamoto J; Takeda T; Ichimura S; Uzawa M
    J Orthop Sci; 2002; 7(6):637-43. PubMed ID: 12486466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rhPTH (1-34), but not elcatonin, increases bone anabolic efficacy in postmenopausal women with osteoporosis.
    Zhang L; Yang M; Liu D; Guo C; Li L; Yang G
    Exp Clin Endocrinol Diabetes; 2012 Jun; 120(6):361-6. PubMed ID: 22639400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled study of once weekly elcatonin in primary postmenopausal osteoporosis.
    Sugimoto T; Shiraki M; Nakano T; Kishimoto H; Ito M; Fukunaga M; Sone T; Hagino H; Miki T; Nishizawa Y; Akachi S; Nakamura T
    Curr Med Res Opin; 2019 Mar; 35(3):447-454. PubMed ID: 29986611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A randomized, multicenter, active-controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with that of elcatonin in postmenopausal women with osteoporosis in China].
    Zhang XZ; Song LG; Wang B; Yang J; Li H; Xuan M; Lei T; Guo XH; Lü XF; Xue QY; Yang GY; Ji QH; Shen J; Liu ZM; Li CJ; Wu TF; Xie HB; Tong JC
    Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):662-6. PubMed ID: 20979784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D.
    Henriksen K; Byrjalsen I; Andersen JR; Bihlet AR; Russo LA; Alexandersen P; Valter I; Qvist P; Lau E; Riis BJ; Christiansen C; Karsdal MA;
    Bone; 2016 Oct; 91():122-9. PubMed ID: 27462009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
    Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
    Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis.
    Cranney A; Tugwell P; Zytaruk N; Robinson V; Weaver B; Shea B; Wells G; Adachi J; Waldegger L; Guyatt G;
    Endocr Rev; 2002 Aug; 23(4):540-51. PubMed ID: 12202469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
    Binkley N; Bolognese M; Sidorowicz-Bialynicka A; Vally T; Trout R; Miller C; Buben CE; Gilligan JP; Krause DS;
    J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, multicenter controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with elcatonin in postmenopausal women with osteoporosis in China.
    Zhang XZ; Wang B; Yang J; Xuan M; Song LG; Li H; Guo XH; Lü XF; Xue QY; Yang GY; Ji QH; Shen J; Liu ZM; Li CJ; Wu TF; Tong XC; Jia Y
    Chin Med J (Engl); 2009 Dec; 122(24):2933-8. PubMed ID: 20137477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: A systematic review and meta-analysis.
    Peng L; Luo Q; Lu H
    Medicine (Baltimore); 2017 Dec; 96(49):e8659. PubMed ID: 29245225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials.
    Wang YK; Qin SQ; Ma T; Song W; Jiang RQ; Guo JB; Li K; Zhang YM
    Medicine (Baltimore); 2017 May; 96(21):e6970. PubMed ID: 28538396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials.
    Han SL; Wan SL
    Int J Clin Pract; 2012 Feb; 66(2):199-209. PubMed ID: 22257045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.